AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 195.58B +21.3% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 25.08 |
| Forward PE | 15.96 |
| Dividend | 2.36 (1.87%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 3,263,326 |
| Open | 12,580 |
| Previous Close | 12,610 |
| Day's Range | 12,328 - 12,590 |
| 52-Week Range | 10,178 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 16,063.55 (+29.92%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,064p, which is an increase of 29.92% from the latest price.
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to...
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform tria...
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)
AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition
AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition
AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M
Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca (AZN) for Zegfrovy, an oral irreversible epidermal growth factor receptor, or EGFR, inhibitor for patient...
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange ...
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e...
Alnylam price target raised to $485 from $470 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alnylam (ALNY) to $485 from $470 and keeps a Buy rating on the shares after AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) recently…
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
NEW YORK--(BUSINESS WIRE)--On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primar...
AstraZeneca downgraded to Hold from Buy at HSBC
HSBC analyst Rajesh Kumar downgraded AstraZeneca (AZN) to Hold from Buy with a price target of 13,750 GBp, down from 16,500 GBp. The firm says the company’s path to over…
FTSE 100 Closes Higher at 10,497.29 as London's Vodafone Surges, EasyJet Takeover Bid Lifts Sentiment
The FTSE 100 index rose on Friday, driven by Vodafone and easyJet deals, despite AstraZeneca's decline and Middle East tensions, highlighting the index's defensive role amid global market volatility.
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned...
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” TradeAstrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its busin...
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years. Analysts estimate the trial miss wiped just 2-4% from their valuation models ...
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.
AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Administration Nomination
AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Administration Nomination
AstraZeneca price target lowered to 17,500 GBp from 18,000 GBp at Citi
Citi lowered the firm’s price target on AstraZeneca (AZN) to 17,500 GBp from 18,000 GBp and keeps a Buy rating on the shares.
AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca
AstraZeneca (AZN) investors lost money after the Company projected "landmark data" from its Phase III Cardio-TTRansform trial; when the results came in, the trial missed its primary endpoint and the s...
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
Wedbush raised the firm’s price target on Intellia Therapeutics to $17 from $12 and keeps a Neutral rating on the shares. Relevant to Intellia Therapeutics (NTLA), AstraZeneca (AZN) and Ionis…
AstraZeneca price target raised to C$190 from C$180 at Stifel
Stifel raised the firm’s price target on AstraZeneca (AZN) to C$190 from C$180 and keeps a Buy rating on the shares.
AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)
AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of...
AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors
AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Tells Investors
AstraZeneca slump weighs on FTSE 100
AstraZeneca shares fell after trial disappointment, while miners, Computacenter and Playtech supported broader market gains. The post AstraZeneca slump weighs on FTSE 100 appeared first on Investomani...